

Annalisa Chiarenza

List of Publications by Citations

Source: <https://exaly.com/author-pdf/6587191/annalisa-chiarenza-publications-by-citations.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

104
papers

2,835
citations

19
h-index

52
g-index

109
ext. papers

3,321
ext. citations

4.6
avg, IF

4.06
L-index

#	Paper	IF	Citations
104	Analysis of the coding genome of diffuse large B-cell lymphoma. <i>Nature Genetics</i> , 2011 , 43, 830-7	36.3	760
103	Inactivating mutations of acetyltransferase genes in B-cell lymphoma. <i>Nature</i> , 2011 , 471, 189-95	50.4	684
102	Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia. <i>Blood</i> , 2015 , 126, 1921-4	2.2	167
101	COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. <i>Leukemia</i> , 2020 , 34, 2354-2363	10.7	118
100	CD200 expression may help in differential diagnosis between mantle cell lymphoma and B-cell chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2009 , 33, 1212-6	2.7	106
99	Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma. <i>Journal of Clinical Oncology</i> , 2018 , 36, 689-696	2.2	81
98	Disulfiram, an old drug with new potential therapeutic uses for human hematological malignancies. <i>International Journal of Cancer</i> , 2012 , 131, 2197-203	7.5	58
97	Circulating myeloid-derived suppressor cells correlate with clinical outcome in Hodgkin Lymphoma patients treated up-front with a risk-adapted strategy. <i>British Journal of Haematology</i> , 2015 , 168, 689-700	4.5	57
96	Granulocyte-like myeloid derived suppressor cells (G-MDSC) are increased in multiple myeloma and are driven by dysfunctional mesenchymal stem cells (MSC). <i>Oncotarget</i> , 2016 , 7, 85764-85775	3.3	56
95	Myeloid derived suppressor cells (MDSCs) are increased and exert immunosuppressive activity together with polymorphonuclear leukocytes (PMNs) in chronic myeloid leukemia patients. <i>PLoS ONE</i> , 2014 , 9, e101848	3.7	55
94	Rituximab maintenance compared with observation after brief first-line R-FND chemoimmunotherapy with rituximab consolidation in patients age older than 60 years with advanced follicular lymphoma: a phase III randomized study by the Fondazione Italiana Linfomi. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3351-9	2.2	48
93	Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia. <i>Journal of Experimental Medicine</i> , 2018 , 215, 681-697	16.6	41
92	Effects of imatinib mesylate in osteoblastogenesis. <i>Experimental Hematology</i> , 2009 , 37, 461-8	3.1	37
91	Biological and clinical implications of mutations in chronic lymphocytic leukemia. <i>Haematologica</i> , 2020 , 105, 448-456	6.6	35
90	Valproate enhances imatinib-induced growth arrest and apoptosis in chronic myeloid leukemia cells. <i>Cancer</i> , 2006 , 106, 1188-96	6.4	33
89	Endoscopic features of gastro-intestinal lymphomas: from diagnosis to follow-up. <i>World Journal of Gastroenterology</i> , 2014 , 20, 12993-3005	5.6	30
88	Prognostic meaning of neutrophil to lymphocyte ratio (NLR) and lymphocyte to monocyte ration (LMR) in newly diagnosed Hodgkin lymphoma patients treated upfront with a PET-2 based strategy. <i>Annals of Hematology</i> , 2018 , 97, 1009-1018	3	28

87	Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study. <i>Haematologica</i> , 2018 , 103, 1209-1217	6.6	24
86	Effects of second-generation tyrosine kinase inhibitors towards osteogenic differentiation of human mesenchymal cells of healthy donors. <i>Hematological Oncology</i> , 2012 , 30, 27-33	1.3	23
85	CD49d promotes disease progression in chronic lymphocytic leukemia: new insights from CD49d bimodal expression. <i>Blood</i> , 2020 , 135, 1244-1254	2.2	18
84	Mesenchymal Stem Cells (MSC) Regulate Activation of Granulocyte-Like Myeloid Derived Suppressor Cells (G-MDSC) in Chronic Myeloid Leukemia Patients. <i>PLoS ONE</i> , 2016 , 11, e0158392	3.7	18
83	Prognostic roles of absolute monocyte and absolute lymphocyte counts in patients with advanced-stage follicular lymphoma in the rituximab era: an analysis from the FOLL05 trial of the Fondazione Italiana Linfomi. <i>British Journal of Haematology</i> , 2015 , 169, 544-51	4.5	16
82	Salvage therapy of multiple myeloma: the new generation drugs. <i>BioMed Research International</i> , 2014 , 2014, 456037	3	16
81	The prognostic value of the myeloid-mediated immunosuppression marker Arginase-1 in classic Hodgkin lymphoma. <i>Oncotarget</i> , 2016 , 7, 67333-67346	3.3	16
80	Combination of bendamustine and rituximab as front-line therapy for patients with chronic lymphocytic leukaemia: multicenter, retrospective clinical practice experience with 279 cases outside of controlled clinical trials. <i>European Journal of Cancer</i> , 2016 , 60, 154-65	7.5	16
79	NOTCH1 mutational status in chronic lymphocytic leukaemia: clinical relevance of subclonal mutations and mutation types. <i>British Journal of Haematology</i> , 2018 , 182, 597-602	4.5	15
78	Prognostic assessment and treatment of primary gastric lymphomas: how endoscopic ultrasonography can help in tailoring patient management. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014 , 14, 179-85	2	15
77	CD200 expression in patients with Multiple Myeloma: another piece of the puzzle. <i>Leukemia Research</i> , 2013 , 37, 1616-21	2.7	15
76	Complementary and alternative medicine use in patients with chronic lymphocytic leukemia: an Italian multicentric survey. <i>Leukemia and Lymphoma</i> , 2014 , 55, 841-7	1.9	15
75	SPARC expression in CML is associated to imatinib treatment and to inhibition of leukemia cell proliferation. <i>BMC Cancer</i> , 2013 , 13, 60	4.8	14
74	Detection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: a proposal for clinical application. <i>Journal of Hematology and Oncology</i> , 2013 , 6, 83	22.4	14
73	Outcome of transformed follicular lymphoma worsens according to the timing of transformation and to the number of previous therapies. A retrospective multicenter study on behalf of Fondazione Italiana Linfomi (FIL). <i>British Journal of Haematology</i> , 2019 , 185, 713-717	4.5	13
72	Rare gastrointestinal lymphomas: The endoscopic investigation. <i>World Journal of Gastrointestinal Endoscopy</i> , 2015 , 7, 928-49	2.2	12
71	Mutations in the 3'Suntranslated region of are associated with low CD20 expression levels chronic lymphocytic leukemia. <i>Haematologica</i> , 2017 , 102, e305-e309	6.6	11
70	Immune off-target effects of Brentuximab Vedotin in relapsed/refractory Hodgkin Lymphoma. <i>British Journal of Haematology</i> , 2019 , 185, 468-479	4.5	11

69	Salvage therapy with pegylated liposomal doxorubicin, bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory myeloma patients. <i>European Journal of Haematology</i> , 2014 , 93, 207-13	3.8	11
68	Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study. <i>Leukemia</i> , 2021 , 35, 235-238	10.7	11
67	KRAS, NRAS, and BRAF mutations are highly enriched in trisomy 12 chronic lymphocytic leukemia and are associated with shorter treatment-free survival. <i>Leukemia</i> , 2019 , 33, 2111-2115	10.7	10
66	Monocytic Myeloid Derived Suppressor Cells in Hematological Malignancies. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	10
65	Endoscopic ultrasonography in gastric lymphomas: appraisal on reliability in long-term follow-up. <i>Hematological Oncology</i> , 2012 , 30, 180-5	1.3	10
64	Immunoglobulin heavy chain variable region gene and prediction of time to first treatment in patients with chronic lymphocytic leukemia: Mutational load or mutational status? Analysis of 1003 cases. <i>American Journal of Hematology</i> , 2018 , 93, E216-E219	7.1	9
63	Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab. <i>Leukemia</i> , 2018 , 32, 1869-1873	10.7	8
62	Mutational status of is the most reliable prognostic marker in trisomy 12 chronic lymphocytic leukemia. <i>Haematologica</i> , 2017 , 102, e443-e446	6.6	8
61	Response-Adapted Postinduction Strategy in Patients With Advanced-Stage Follicular Lymphoma: The FOLL12 Study. <i>Journal of Clinical Oncology</i> , 2021 , JCO2101234	2.2	7
60	Brentuximab vedotin in association with bendamustine in refractory or multiple relapsed Hodgkin lymphoma. A retrospective real-world study. <i>European Journal of Haematology</i> , 2020 , 104, 581-587	3.8	6
59	Imatinib increases cytotoxicity of melphalan and their combination allows an efficient killing of chronic myeloid leukemia cells. <i>European Journal of Haematology</i> , 2011 , 86, 216-25	3.8	6
58	A laboratory-based scoring system predicts early treatment in Rai 0 chronic lymphocytic leukemia. <i>Haematologica</i> , 2020 , 105, 1613-1620	6.6	6
57	Predictive value of the CLL-IPI in CLL patients receiving chemo-immunotherapy as first-line treatment. <i>European Journal of Haematology</i> , 2018 , 101, 703	3.8	5
56	Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib-rituximab. <i>Blood Cancer Journal</i> , 2020 , 10, 92	7	5
55	Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study. <i>American Journal of Hematology</i> , 2021 , 96, E168-E171	7.1	5
54	Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile. <i>Leukemia Research</i> , 2014 , 38, 198-203	2.7	4
53	Brief Chemoimmunotherapy R-FND with Rituximab Consolidation Followed by Randomization Between Rituximab Maintenance Vs. Observation As First Line Treatment in Elderly Patients with Advanced Follicular Lymphoma (FL): Final Results of a Prospective Randomized Trial by Italian Lymphoma Foundation (FIL). <i>Blood</i> , 2011 , 118, 777-777	2.2	4
52	SF3B1-mutated chronic lymphocytic leukemia shows evidence of NOTCH1 pathway activation including CD20 downregulation. <i>Haematologica</i> , 2021 , 106, 3125-3135	6.6	4

51	Neutrophils Of Multiple Myeloma Are Dysfunctional and Immunosuppressive. <i>Blood</i> , 2013 , 122, 3138-3138	3
50	Impaired nodal shrinkage and apoptosis define the independent adverse outcome of NOTCH1 mutated patients under ibrutinib therapy in chronic lymphocytic leukaemia. <i>Haematologica</i> , 2021 , 106, 2345-2353	6.6 3
49	TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases. <i>American Journal of Hematology</i> , 2021 , 96, E306-E310	7.1 3
48	A brief rituximab, bendamustine, mitoxantrone (R-BM) induction followed by rituximab consolidation in elderly patients with advanced follicular lymphoma: a phase II study by the Fondazione Italiana Linfomi (FIL). <i>British Journal of Haematology</i> , 2021 , 193, 280-289	4.5 3
47	Mutations with Low Variant Allele Frequency Predict Short Survival in Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , 2021 , 27, 5566-5575	12.9 3
46	Clinical Relevance of NOTCH1 Mutations in Ibrutinib-Treated Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2018 , 132, 4396-4396	2.2 2
45	Monocytic Myeloid Derived Suppressor CELLS (M-MDSC) As Prognostic Factor in Chronic Myeloid Leukemia Patients Treated with Dasatinib. <i>Blood</i> , 2015 , 126, 2767-2767	2.2 2
44	Telbivudine use in a patient affected by occult hepatitis B virus and B-cell non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2010 , 51, 554-7	1.9 1
43	Role of Age, Fitness and Concomitant Medications in CLL Patients Treated with Venetoclax. <i>Blood</i> , 2020 , 136, 25-26	2.2 1
42	CD200 Expression May Help in Differential Diagnosis between Mantle Cell Lymphoma (MCL) and B-Cell Chronic Lymphocytic Leukemia (B-CLL).. <i>Blood</i> , 2007 , 110, 4672-4672	2.2 1
41	Brief Chemoimmunotherapy Rituximab, Bendamustine, Mitoxantrone (R-BM) Followed by Rituximab Consolidation in Elderly Patients with Untreated Advanced Stage Follicular Lymphoma (FL): Preliminary Results of a Prospective Phase II Study by Fondazione Italiana Linfomi (FIL).. <i>Blood</i> , 2012 , 120, 2720-2720	2.2 1
40	Arginase 1 Is a Marker of Myeloid-Mediated Immunosuppression with Prognostic Meaning in Classic Hodgkin Lymphoma. <i>Blood</i> , 2016 , 128, 1770-1770	2.2 1
39	Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases. <i>European Journal of Haematology</i> , 2021 , 106, 493-499	3.8 1
38	Mutations of the Exportin 1 (XPO1) Gene Predict Shorter Time to First Treatment in 1092 Early Stage Chronic Lymphocytic Leukemia Patients. Training/Validation Study. <i>Blood</i> , 2020 , 136, 31-32	2.2 0
37	An Observational Study on Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Treated with Venetoclax-Based Regimens Outside Clinical Trials in Italy (GIMEMA CLL1920). <i>Blood</i> , 2021 , 138, 3746-3746	2.2 0
36	Efficacy of Idelalisib and Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Treated Outside of Clinical Trial. a Report of the Gimema Group. <i>Blood</i> , 2020 , 136, 23-25	2.2
35	Safety Profile of Idelalisib in Patients with Refractory Follicular Lymphoma: Interim Analysis of a Noninterventional Study. <i>Blood</i> , 2020 , 136, 48-50	2.2
34	Do Age, Fitness and Concomitant Medications Influence Management and Outcomes of CLL Patients Treated with Ibrutinib?. <i>Blood</i> , 2020 , 136, 54-55	2.2

- 33 In Vitro Cytotoxicity of Alemtuzumab on B-CLL Cells: Differential Effect on B and T Lymphocytes.. *Blood*, **2006**, 108, 4981-4981 2.2
- 32 Hypoxia Induces Imatinib Resistance in CML Cell Lines.. *Blood*, **2006**, 108, 4387-4387 2.2
- 31 Role of Imatinib Mesylate in Osteoblastogenesis.. *Blood*, **2007**, 110, 1928-1928 2.2
- 30 Salvage Therapy with Intravenous Bortezomib, Melphalan and Dexamethasone in Previously Treated Myeloma Patients.. *Blood*, **2007**, 110, 2728-2728 2.2
- 29 The VLA-4 Integrin Is Constitutively Activated in a Subset of CD49d-Expressing CLL: A Relationship with the Autonomous BCR-Mediated Signaling?. *Blood*, **2018**, 132, 5531-5531 2.2
- 28 Intraclonal Diversification Occurs in Chronic Lymphocytic Leukemia Expressing B Cell Receptors Belonging to the IGHV4 Gene Family. *Blood*, **2018**, 132, 944-944 2.2
- 27 SF3B1 Mutations Associate with Low CD20 Expression in CLL: Another NOTCH1-Dependent Mechanism?. *Blood*, **2018**, 132, 1838-1838 2.2
- 26 Clinical Impact of Clonal and Subclonal TP53 Mutations in Chronic Lymphocytic Leukemia. *Blood*, **2018**, 132, 945-945 2.2
- 25 KRAS, NRAS and BRAF Mutations Are Highly Enriched in TRI12 Chronic Lymphocytic Leukemia and Are Associated to Shorter Time to First Treatment. *Blood*, **2018**, 132, 3113-3113 2.2
- 24 A Laboratory Based Scoring System Predicts Early Treatment in Rai 0/Binet a CLL. *Blood*, **2018**, 132, 4399-4399 2.2
- 23 Updated results of the FOLL05 phase III trial from the Fondazione Italiana Linfomi comparing R-CVP, R-CHOP, and R-FM in patients with advanced follicular lymphoma.. *Journal of Clinical Oncology*, **2014**, 32, 8530-8530 2.2
- 22 Up-Regulation of Prok-2 in Granulocytes Is Present BOTH in MGUS and MM. *Blood*, **2014**, 124, 5694-5694 2.2
- 21 A Molecular Model to Predict Durable Remission after First Line Fludarabine-Cyclophosphamide-Rituximab Treatment in Chronic Lymphocytic Leukemia. *Blood*, **2014**, 124, 3300-3300 2.2
- 20 Arginase-1 Is Increased in Hodgkin Lymphoma, Associated to Poor Outcome and Positively Correlated to Semiquantitative PET Parameters. *Blood*, **2014**, 124, 4401-4401 2.2
- 19 Retention of inside-out VLA-4 Integrin Activation upon B-Cell Receptor Triggering in in-Vitro and in-Vivo Ibrutinib Treated Chronic Lymphocytic Leukemia Cells: Clinical Implication. *Blood*, **2015**, 126, 1708-1708 2.2
- 18 Management of Grade 3B Follicular Lymphoma (FL) Outside Clinical Trials: A Multicentric Retrospective Analysis on Behalf of Fondazione Italiana Linfomi (FIL). *Blood*, **2015**, 126, 2716-2716 2.2
- 17 Outcome of Transformed FL(t-FL) Worsens According to the Timing of Transformation and to the Number of Previous Therapies. A Survey of the Fondazione Italiana Linfomi (FIL). *Blood*, **2015**, 126, 3933-3933 2.2
- 16 Mesenchymal STEM CELLS Favor Tumor Growth By Generating Granulocyte-like Myeloid Derived Suppressor CELLS in CML Patients. *Blood*, **2015**, 126, 4018-4018 2.2

- 15 The Concomitant High Expression of the B-Cell Receptor Signaling Inhibitor Molecules CD150, CD305, and CD307b Predicts Longer Overall Survival in the Context of Low-Risk Chronic Lymphocytic Leukemia. *Blood*, **2015**, 126, 1720-1720 2.2
- 14 LONG-TERM Outcome of a Fondazione Italiana Linfomi Study Comparing Short Rituximab Maintenance Vs Observation after Brief First-LINE R-FND Chemoimmunotherapy Followed By Rituximab Consolidation in Elderly Patients with Advanced Follicular Lymphoma (FL). *Blood*, **2015**, 126, 3985-3985 2.2
- 13 The Combined Evaluation of Neutrophil, T-Lymphocyte and Monocyte Counts Provides New Prognostic Information in CLL Patients. *Blood*, **2016**, 128, 5565-5565 2.2
- 12 Mutations at 3'Untranslated Region (3'UTR) of NOTCH1 Are Associated with Low CD20 Expression Levels in Chronic Lymphocytic Leukemia. *Blood*, **2016**, 128, 306-306 2.2
- 11 Lack of Prognostic Significance of the Conventional and Novel Prognostic Markers in Trisomy 12 Chronic Lymphocytic Leukemia (CLL). *Blood*, **2016**, 128, 4354-4354 2.2
- 10 Comprehensive Characterization of NOTCH1 Mutational Status in Chronic Lymphocytic Leukemia: Clinical Relevance of Subclonal Mutations and Mutation Types. *Blood*, **2016**, 128, 3195-3195 2.2
- 9 The B-Cell Receptor Signaling Inhibitor Molecules CD305 and CD307b Are Markers of Favorable Prognosis in Chronic Lymphocytic Leukemia with Both Mutated and Unmutated IGHV Gene Status. *Blood*, **2016**, 128, 4358-4358 2.2
- 8 Role of New Tyrosine Kinase Inhibitors in Osteoblastogenesis. *Blood*, **2008**, 112, 4751-4751 2.2
- 7 Variation of T-Reg and CD 200+ T- Lymphocytes After in Vitro Treatment with Active Drugs against CLL.. *Blood*, **2009**, 114, 1239-1239 2.2
- 6 Myeloid-Derived Suppressor Cells in Patients with Hodgkin Lymphoma.. *Blood*, **2009**, 114, 3662-3662 2.2
- 5 High Response Rate with Favorable Survival Projections in High-Risk Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Receiving R-CHOP-14 or Early Intensified Chemotherapy with Rituximab and Autograft (R-HDS): Results of the Interim Analysis of A GITIL Prospective Multicenter Phase III Study.. *Blood*, **2009**, 114, 1220-1220 2.2
- 4 Absolute Count of Myeloid Derived Suppressor Cells (MDSC) Is Able to Predict the Response to Early-PET In Hodgkin Lymphoma. *Blood*, **2010**, 116, 3882-3882 2.2
- 3 Genome-Wide Analysis Reveals Frequent Inactivating Mutations of Acetyltransferase Genes In B-Cell Lymphoma. *Blood*, **2010**, 116, 474-474 2.2
- 2 Myeloid Derived Suppressor Cells (MDSCs) Are Increased and Exert Immunosuppressive Activity In CML Patients At Diagnosis. *Blood*, **2013**, 122, 2711-2711 2.2
- 1 Myeloid Cells Exert Immunosuppressive Activity and Have Prognostic Value In Hodgkin Lymphoma. *Blood*, **2013**, 122, 4238-4238 2.2